All In Biotech

Drug Trial Radar · NCT03874832

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Nov 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Sep 11, 2018

Primary completion

Nov 7, 2018

Study completion Nov 7, 2018

Sponsor

Lead sponsor
Satsuma Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.

Conditions

  • Migraine With Aura
  • Migraine Without Aura
  • Migraine

Interventions

  • DihydroergotamineDrug

    Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. STS101 Dose Selection - Part 1Time frame: Pre-dose through 48 hours post-dose
  2. DHE Relative Bioavailability - Part 2Time frame: Pre-dose through 48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences Miami Inc.

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.